Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283440 | 0.85 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL4972941 | 0.85 | TRPV1 (0.68) | TRPV1 | |
| SCHEMBL4972967 | 0.83 | TRPV1 (0.64) | TRPV1 | |
| SCHEMBL27600601 | 0.82 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL4977870 | 0.81 | TRPV1 (0.59) | TRPV1 | |
| SCHEMBL4353069 | 0.81 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL4908457 | 0.80 | TRPV1 (0.84) | TRPV1 | |
| SCHEMBL4984341 | 0.80 | TRPV1 (0.53) | TRPV1 | |
| Hydrochloric Acid SCHEMBL4914803 | 0.80 | TRPV1 (0.82) | TRPV1 | |
| SCHEMBL4973179 | 0.80 | TRPV1 (0.54) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-7432275-B2 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432275-B2 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432275-B2 | Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators | NEUROGEN CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-06-26 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329664-B2 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | NEUROGEN CORPORATION (US) | 2008-02-12 | — | — | US | disclosed |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
| CN-1627944-A | Substituted quinazolin-4-ylamine analogues as capsaicin modulators | NEUROGEN CORP (US) | 2005-06-15 | — | — | CN | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004055004-A1 | CARBOXYLIC ACID, PHOSPHATE OR PHOSPHONATE SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | TRPV1 36/4885 |
| US-20050165032-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | TRPV1 1/4885 |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 297/4885 |
| US-20080153857-A1 | Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues | GPR27, GPR88, MUSK | TRPV1 211/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | TRPV1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.